# Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

> **NCT03422874** · PHASE1 · WITHDRAWN · sponsor: **Dartmouth-Hitchcock Medical Center**

## Conditions studied

- Neoplasms
- Lymphoma

## Interventions

- **DRUG:** MLN9708
- **DRUG:** Nelfinavir

## Key facts

- **NCT ID:** NCT03422874
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08
- **Primary completion:** 2017-08-04
- **Final completion:** 2017-08-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor withdrew support
- **Last updated:** 2018-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03422874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03422874, "Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT03422874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*